Study: Baeten 2012, New England Journal of Medicine
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
Citation
Baeten JM, Donnell D, Ndase P, Mugo NR et al (2012). New England Journal of Medicine. PubMed id 22784037.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- HIV prevention, testing and PrEP Tier A strong
A 4,758 heterosexual HIV-serodiscordant couples in Kenya and Uganda; the HIV-negative partner (62% male) took tenofovir, tenofovir-emtricitabine or placebo (n=4758)
Randomised, double-blind, placebo-controlled trial (Partners PrEP), follow-up up to 36 months.
Of 82 HIV infections in the HIV-negative partners, 17 were in the tenofovir group (0.65 per 100 person-years), 13 in the tenofovir-emtricitabine group (0.50) and 52 in the placebo group (1.99). That is a 67% reduction with tenofovir (95% CI 44 to 81) and 75% with the combination (95% CI 55 to 87).
As recorded in this card: Baeten JM, Donnell D, Ndase P, Mugo NR et al (2012), New England Journal of Medicine, [primary]
Note: East African couples; the abstract was cut off before the adherence analysis, so the effect of taking every dose is not stated here.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.